[
    [
        {
            "time": "2021-02-03",
            "original_text": "Wind医药：每日行业动态（2021-02-03）",
            "features": {
                "keywords": [
                    "药品集采",
                    "创新药产业",
                    "业绩预计大增"
                ],
                "sentiment_score": 0.7,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Wind医药：每日行业动态（2021-02-03）",
                "Correlation": 4,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 3,
                "Duration": 4,
                "Entity_Density": 2,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 5,
                "Source_Recency": 6
            }
        },
        {
            "time": "2021-02-03",
            "original_text": "港股异动︱药明康德(02359)涨超6% 大和上调其目标价36.8%至238港元并予以“跑赢大市”评级",
            "features": {
                "keywords": [
                    "药明康德",
                    "目标价上调",
                    "跑赢大市"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "港股异动︱药明康德(02359)涨超6% 大和上调其目标价36.8%至238港元并予以“跑赢大市”评级",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-02-03",
            "original_text": "再融资新规实施一年：增发规模同比增四成 知名外资机构踊跃抢购A股核心资产",
            "features": {
                "keywords": [
                    "再融资新规",
                    "增发规模",
                    "外资抢购"
                ],
                "sentiment_score": 0.8,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "A股核心资产"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "再融资新规实施一年：增发规模同比增四成 知名外资机构踊跃抢购A股核心资产",
                "Correlation": 5,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-02-03",
            "original_text": "中泰国际：药明康德旗下合全药业收购BMY US生产基地",
            "features": {
                "keywords": [
                    "药明康德",
                    "合全药业",
                    "海外产能收购"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "中泰国际：药明康德旗下合全药业收购BMY US生产基地",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-02-03",
            "original_text": "浙商证券给予药明康德买入评级，药明康德事件点评：CDMO布局新动向，海外产能收购",
            "features": {
                "keywords": [
                    "药明康德",
                    "CDMO布局",
                    "海外产能收购"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "浙商证券给予药明康德买入评级，药明康德事件点评：CDMO布局新动向，海外产能收购",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-02-03",
            "original_text": "医药生物2月月报：寻业绩主线 重点关CXO等高增长赛道",
            "features": {
                "keywords": [
                    "医药生物",
                    "CXO",
                    "高增长赛道"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药生物2月月报：寻业绩主线 重点关CXO等高增长赛道",
                "Correlation": 6,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 7,
                "Entity_Density": 4,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "2021-02-03",
            "original_text": "权益变动】药明康德(02359-HK)获Wellington Management增持1.1603万股",
            "features": {
                "keywords": [
                    "药明康德",
                    "Wellington Management",
                    "增持"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "权益变动】药明康德(02359-HK)获Wellington Management增持1.1603万股",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-02-03",
            "original_text": "权益变动】药明康德(02359-HK)被FMRLLC减持78.51万股",
            "features": {
                "keywords": [
                    "药明康德",
                    "FMRLLC",
                    "减持"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "权益变动】药明康德(02359-HK)被FMRLLC减持78.51万股",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        }
    ]
]